SequelSEC

BIO-TECHNE Corp TECH

Biological Products, (No Diagnostic Substances) · CIK 0000842023 · Fiscal year ends 0630

AnnualQuarterlyTTM
Revenue
$321.19M
Fiscal year ended 2026-06-30
Operating income
$74.28M
Fiscal year ended 2026-06-30
Free cash flow
$86.94M
Fiscal year ended 2026-06-30

BIO-TECHNE Corp (TECH) reported revenue of $321.19M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from BIO-TECHNE Corp’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

BIO-TECHNE Corp income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$321.19M$311.42M$295.88M$286.56M$316.96M$316.18M$297.03M$289.46M$306.10M$303.43M
Cost of revenue$109.80M$103.13M$104.60M$98.44M$118.15M$101.62M$103.14M$106.44M$102.75M$98.83M
Gross profit$211.39M$208.29M$191.28M$188.11M$198.81M$214.56M$193.89M$183.02M$203.35M$204.60M
Operating income$74.28M$75.50M$54.46M$47.66M-$23.86M$38.71M$47.42M$39.99M$45.82M$67.00M
Net incomeUnavailable$51.05M$38.01M$38.18M-$17.68M$22.59M$34.89M$33.60M$40.59M$49.06M
Research & developmentUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesUnavailableshares 157.40Mshares 157.00Mshares 156.36MUnavailableshares 158.94Mshares 160.63Mshares 161.12MUnavailableshares 160.50M
Pretax income$70.68M$71.22M$50.78M$47.99M-$22.86M$38.27M$42.88M$40.17M$41.66M$61.08M
Income tax expense$16.06M$20.18M$12.78M$9.81M-$5.18M$15.69M$7.99M$6.57M$1.07M$12.02M
Diluted EPSUnavailable$0.32$0.24$0.24Unavailable$0.14$0.22$0.21Unavailable$0.31
Selling, general & administrative$113.17M$109.34M$113.69M$116.21M$196.64M$151.27M$121.45M$119.16M$133.54M$111.84M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

BIO-TECHNE Corp balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$264.71M$209.82M$172.88M$144.96M$162.19M$140.67M$177.55M$187.54M$151.79M$139.92M
Total assets$2.59B$2.55B$2.52B$2.53B$2.56B$2.64B$2.67B$2.74B$2.70B$2.72B
Current assets$744.40M$688.05M$637.43M$609.51M$608.30M$627.24M$634.64M$648.57M$617.42M$610.65M
Total liabilitiesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current liabilities$163.70M$153.28M$140.43M$144.54M$175.85M$169.20M$161.26M$142.13M$159.38M$149.82M
Total equity incl. NCI$2.11B$2.09B$2.01B$1.97B$1.92B$2.02B$2.08B$2.14B$2.07B$2.01B
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$195.74M$201.18M$205.45M$203.19M$189.45M$191.08M$188.37M$185.04M$179.73M$179.50M
Accounts receivable$216.58M$214.56M$184.61M$183.90M$206.88M$237.14M$217.94M$223.69M$241.39M$227.89M
Goodwill$975.36M$977.80M$980.56M$978.91M$980.94M$968.61M$964.61M$982.58M$972.66M$970.97M
Long-term debt$200.00M$200.00M$260.00M$300.00M$346.00M$330.00M$300.00M$300.00M$319.00M$389.00M
Accounts payable$26.70M$23.49M$26.27M$30.16M$25.31M$31.64M$33.12M$31.56M$37.97M$28.90M

Cash flow

BIO-TECHNE Corp cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow$95.42M$86.66M$82.41M$27.58M$98.20M$41.12M$84.35M$63.89M$75.50M$80.99M
Capital expenditures$8.48M$9.09M$5.92M$5.36M$4.89M$10.12M$6.82M$9.17M$17.98M$16.44M
Investing cash flow-$7.06M-$5.82M-$5.92M$605.00K$406.00K-$8.87M-$5.03M-$21.68M-$8.81M-$16.44M
Financing cash flow-$33.21M-$42.72M-$48.99M-$44.20M-$90.45M-$68.04M-$83.84M-$11.57M-$60.10M-$52.42M
Net change in cash$54.89M$36.94M$27.92M-$17.22M$21.52M-$36.88M-$9.99M$35.75M$11.88M$9.78M
Stock-based compensation$5.23M$10.50M$13.96M$11.68M$4.55M$11.39M$14.71M$10.18M$7.06M$8.13M
Common dividends paid$12.48M$12.52M$12.47M$12.44M$12.39M$12.58M$12.74M$12.69M$12.63M$12.58M
Common share repurchases$41.65M$0$0$24.00K$100.06M$100.05MUnavailableUnavailable$0$0
Depreciation & amortization$24.14M$24.17M$24.71M$24.34M$27.11M$27.57M$27.08M$28.14M$28.06M$27.31M

Derived

BIO-TECHNE Corp derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow$86.94M$77.58M$76.49M$22.22M$93.31M$31.00M$77.52M$54.72M$57.52M$64.54M
Gross margin65.8%66.9%64.6%65.6%62.7%67.9%65.3%63.2%66.4%67.4%
Operating margin23.1%24.2%18.4%16.6%-7.5%12.2%16.0%13.8%15.0%22.1%
FCF margin27.1%24.9%25.9%7.8%29.4%9.8%26.1%18.9%18.8%21.3%
SBC / revenue1.6%3.4%4.7%4.1%1.4%3.6%5.0%3.5%2.3%2.7%
Current ratio4.55x4.49x4.54x4.22x3.46x3.71x3.94x4.56x3.87x4.08x
Revenue YoY growth1.3%-1.5%-0.4%-1.0%3.5%4.2%9.0%4.5%1.6%3.2%
Net marginUnavailable16.4%12.8%13.3%Unavailable7.1%11.7%11.6%Unavailable16.2%
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenue2.6%2.9%2.0%1.9%1.5%3.2%2.3%3.2%5.9%5.4%
Long-term debt / equity0.09x0.10xUnavailableUnavailable0.18xUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rate22.7%28.3%25.2%20.4%Unavailable41.0%18.6%16.4%2.6%19.7%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open TECH in the interactive workspace to inspect any figure back to its filing.

Source filings

10-K · Filed 2026-08-24View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-Q · Filed 2026-02-04View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-K · Filed 2025-08-22View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.